SARS-CoV-2-specific antibodies are secreted into human milk after women are vaccinated against COVID-19, which might protect the breastfed infant. Due to several reports of severe side-effects of the Oxford-AstraZeneca ChAdOx1 (AZD1222) vaccine against COVID-19, some lactating women followed a heterologous vaccination schedule consisting of the first dose of AZD1222 and a second dose of an mRNA-based vaccine. However, it is unclear whether this generates a significant SARS-CoV-2-specific antibody response in human milk.
Main Issue
To quantify the SARS-CoV-2-specific antibody response in human milk of two lactating women receiving a heterologous vaccination schedules: AZD1222 and mRNA-based vaccine (Pfizer-BioNTech [BNT162b2] and Moderna [mRNA-1273]).
Management
Both participants collected 16 samples of human milk longitudinally. SARS-CoV-2-specific Immunoglobulin A was measured using an enzyme-linked immunosorbent assay.
Conclusion
Based on our results, it could be suggested that heterologous vaccination with AZD1222 and an mRNA-based vaccine can elicit a significant SARS-CoV-2 specific IgA response in human milk.
AuritiC.De RoseD. U.MondìV.StolfiI.TziallaC, on behalf of the Study Group of Neonatal Infectious Diseases. (2021). Neonatal SARS-CoV-2 infection: Practical tips. Pathogens, 10(5), 611. https://www.mdpi.com/2076-0817/10/5/611
2.
BorobiaA. M.CarcasA. J.Pérez-OlmedaM.CastañoL.BertranM. J.García-PérezJ.CampinsM.PortolésA.González-PérezM.García MoralesM. T.Arana-ArriE.AldeaM.Díez-FuertesF.FuentesI.AscasoA.LoraD.Imaz-AyoN.Barón-MiraL. E.AgustíA.. . . TorviscoJ. M. (2021). Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): A multicentre, open-label, randomised, controlled, Phase 2 trial. The Lancet, 398(10295), 121–130. https://doi.org/10.1016/S0140-6736(21)01420-3
3.
ChanR. W. Y.LiuS.CheungJ. Y.TsunJ. G. S.ChanK. C.ChanK. Y. Y.FungG. P. G.LiA. M.LamH. S. (2021). The mucosal and serological immune responses to the novel Coronavirus (SARS-CoV-2) vaccines. Frontiers in Immunology, 12. 744887. https://www.frontiersin.org/article/10.3389/fimmu.2021.744887
4.
CollierA. Y.McMahanK.YuJ.TostanoskiL. H.AguayoR.AnselJ.ChandrashekarA.PatelS.Apraku BondzieE.SellersD.BarrettJ.SanbornO.WanH.ChangA.AniokeT.NkololaJ.BradshawC.Jacob-DolanC.FeldmanJ.. . . BarouchD. H. (2021). Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. JAMA, 325(23), 2370–2380. https://doi.org/10.1001/jama.2021.7563
5.
De RoseD. U.SalvatoriG.DottaA.AuritiC. (2022). SARS-CoV-2 vaccines during pregnancy and breastfeeding: A systematic review of maternal and neonatal outcomes. Viruses, 14(3), 539. https://www.mdpi.com/1999-4915/14/3/539
6.
GreinacherA.ThieleT.WarkentinT. E.WeisserK.KyrleP. A.EichingerS. (2021). Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. New England Journal of Medicine, 384(22), 2092–2101. https://doi.org/10.1056/NEJMoa2104840
7.
JunckerH. G.MullenersS. J.CoenenE. R. M.van GoudoeverJ. B.van GilsM. J.van KeulenB. J. (2022, March14). Comparing human milk antibody response after 4 different vaccines for COVID-19. JAMA Pediatrics. e220084. https://doi.org/10.1001/jamapediatrics.2022.0084
8.
JunckerH. G.MullenersS. J.van GilsM. J.de GrootC. J. M.PajkrtD.KorosiA.van GoudoeverJ. B.van KeulenB. J. (2021, August). The levels of SARS-CoV-2 specific antibodies in human milk following vaccination. Journal of Human Lactation, 37(3), 477–484. https://doi.org/10.1177/08903344211027112
NordströmP.BallinM.NordströmA. (2021). Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. The Lancet Regional Health - Europe, 11, Article 100249. https://doi.org/10.1016/j.lanepe.2021.100249
11.
NormarkJ.VikströmL.GwonY.-D.PerssonI.-L.EdinA.BjörsellT.DernstedtA.ChristW.TevellS.EvanderM.KlingströmJ.AhlmC.ForsellM. (2021). Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. New England Journal of Medicine, 385(11), 1049–1051. https://doi.org/10.1056/NEJMc2110716
12.
PerlS. H.Uzan-YulzariA.KlainerH.AsiskovichL.YoungsterM.RinottE.YoungsterI. (2021). SARS-CoV-2-specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women. JAMA, 325(19), 2013–2014. https://doi.org/10.1001/jama.2021.5782
13.
SablerollesR. S. G.RietdijkW. J. R.GoorhuisA.PostmaD. F.VisserL. G.GeersD.SchmitzK. S.Garcia GarridoH. M.KoopmansM. P. G.DalmV. A. S. H.KootstraN. A.HuckriedeA. L. W.LafeberM.van BaarleD.GeurtsvanKesselC. H.de VriesR. D.van der KuyP. H. M. (2022). Immunogenicity and reactogenicity of vaccine boosters after Ad26.COV2.S priming. New England Journal of Medicine, 386(10), 951–963. https://doi.org/10.1056/NEJMoa2116747
World Health Organization, & United Nations Children’s Fund. (2021). Indicators for assessing infant and young child feeding practices: Definitions and measurement methods.
16.
YanZ.-P.YangM.LaiC.-L. (2021). COVID-19 Vaccines: A review of the safety and efficacy of current clinical trials. Pharmaceuticals, 14(5), 406. https://doi.org/10.3390/ph14050406
17.
YoungB. E.SeppoA. E.DiazN.Rosen-CaroleC.Nowak-WegrzynA.Cruz VasquezJ. M.Ferri-HuertaR.Nguyen-ContantP.FitzgeraldT.SangsterM. Y.TophamD. J.JärvinenK. M. (2021). Association of human milk antibody induction, persistence, and neutralizing capacity with SARS-CoV-2 infection vs mRNA vaccination. JAMA Pediatrics, 176(2), 159–168. https://doi.org/10.1001/jamapediatrics.2021.4897
